

# Pneumococcal Vaccine Recommendations

## 2023 Updates

**In 2023, the Advisory Committee on Immunization Practices (ACIP) updated the recommendations for pneumococcal conjugate vaccines (PCV) for those aged 19-64 as well as those age 65 and older. Additionally, the recommended vaccine series differs for those who have chronic or immunocompromising conditions. New recommendations also include guidance on future vaccine series according to pneumococcal vaccine history.<sup>1</sup>**

*The guidance, best practices, and guidelines (referred to as “best practices”) provided to you are presented for your consideration and assessment only. They were selected from among best practices published by various associations and organizations or discussed in studies and articles on the subject. Please assess whether the described best practices are appropriate for you. There are no requirements that you use the best practices, and the best practices are not required for any Highmark program or initiative. Please note that the successful implementation of any program or initiative depends upon many factors and variables. Therefore, Highmark makes no representation with respect to the described best practices and whether the practices will positively impact your reimbursement, value-based payment or performance under a Highmark program or initiative.*

*The best practices are not intended to situate Highmark as a provider of medical services or dictate the diagnosis, care or treatment of patients. Your medical judgment remains independent with respect to all medically necessary care to your patients.*

*The information provided is general information only and not intended to address specific circumstances; and the provision of such information does not constitute endorsement of any specific third-party vendor.*


*The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Western and Northeastern PA: Highmark Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Choice Company, Highmark Health Insurance Company, Highmark Coverage Advantage Inc., Highmark Benefits Group Inc., First Priority Health, First Priority Life or Highmark Senior Health Company. Central and Southeastern PA: Highmark Inc. d/b/a Highmark Blue Shield, Highmark Benefits Group Inc., Highmark Health Insurance Company, Highmark Choice Company or Highmark Senior Health Company. Delaware: Highmark BCBSD Inc. d/b/a Highmark Blue Cross Blue Shield. West Virginia: Highmark West Virginia Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Health Insurance Company or Highmark Senior Solutions Company. Western NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Cross Blue Shield. Northeastern NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Shield. All references to “Highmark” in this document are references to the Highmark company that is providing the member’s health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.*



# Pneumococcal Vaccine Recommendations for Adults ≥ 65 Years and 19-64 Years with Chronic or Immunocompromising Conditions

- In 2021, two new pneumococcal vaccines were licensed by the Food and Drug Administration (FDA) for adults ≥ 18 years, PCV15 (Vaxneuvance®) and PCV20 (Pevnar-20®).<sup>2</sup> These two vaccines have shown efficacy against unique serotypes of pneumococcal disease in patients over 65 years and patients 19-64 years with underlying medical conditions.<sup>3</sup>
- The 2023 updates to the ACIP recommendations specify the use of **either PCV20 alone or PCV15 in series with Pneumococcal Polysaccharide Vaccine-23 (PPSV-23, Pneumovax23®)** for all adults aged ≥ 65 years and for adults aged 19-64 with certain underlying medical conditions or other risk factors who have not received a PCV or whose vaccination history is unknown.<sup>3</sup>
- ACIP recommends use of **either a single dose of PCV20 or ≥ 1 dose of PPSV23 for adults who have started their pneumococcal vaccine series with PCV13 but have not received all recommended PPSV23 doses.**
  - Shared clinical decision-making is recommended regarding use of a supplemental PCV20 dose for adults aged ≥65 years who have completed their recommended vaccine series with both PCV13 and PPSV23.<sup>3</sup>
- Updated and new clinical guidance for implementation from the Centers for Disease Control and Prevention (CDC) includes the recommendation for use of **PCV15 or PCV20 for adults who have received PPSV23 but have not received any PCV dose.** The report also includes clinical guidance for adults who have received 7-valent PCV (PCV7) only.<sup>3</sup>

## Adults ≥ 65 Years Complete Pneumococcal Vaccine Schedules<sup>4</sup>




\*May consider minimum of 8-week interval for immunocompromised adults, cochlear implant or cerebral spinal fluid (CSF) leak)

\*\*For adults with an immunocompromising condition, cochlear implant, or CSF leak, the minimum interval for PPSV23 is ≥8 weeks since last PCV13 dose and ≥5 years since last PPSV23 dose; for others, the minimum interval for PPSV23 is ≥1 year since last PCV13 dose and ≥ 5 years since last PPSV23 dose

\*\*\*Together with the patient, vaccine providers may choose to administer PCV20 to adults > 65 years old who have already received PCV13 (but not PCV15 or PCV20) at any age and PPSV23 at or after the age of 65 years old.

# Adults 19-64 Years Old with Specified Immunocompromising Conditions Complete Pneumococcal Vaccine Schedules<sup>4</sup>


Immunocompromising Conditions
Chronic Renal Failure
Congenital or Acquired Asplenia
Congenital or Acquired Immunodeficiency
Generalized malignancy
HIV Infection
Hodkin Disease
Iatrogenic Immunosuppression
Leukemia
Lymphoma
Multiple Myeloma
Nephrotic Syndrome
Sickle Cell Disease/Other Hemoglobinopathies
Solid Organ Transplant



\*Review pneumococcal vaccine recommendations again when your patient turns 65 years old.

# Adults 19-64 Years Old with Chronic Health Conditions Complete Pneumococcal Vaccine Schedules<sup>4</sup>

Chronic Health Conditions
Alcoholism
Chronic Heart Disease, including Congestive Heart Failure
Chronic Liver Disease
Chronic Lung Disease, including Chronic Obstructive Pulmonary Disease, Emphysema, and Asthma
Cigarette Smoking
Diabetes Mellitus
Iatrogenic Immunosuppression
Leukemia
Lymphoma
Multiple Myeloma
Nephrotic Syndrome
Sickle Cell Disease/Other Hemoglobinopathies
Solid Organ Transplant



\*Review pneumococcal vaccine recommendations again when your patient turns 65 years old.

## APPENDIX

### PRESCRIBER CONSIDERATIONS

#### PNEUMOCOCCAL VACCINE CONSIDERATIONS<sup>3</sup>

- Shared clinical decision-making is recommended regarding PCV20 use for adults aged **≥ 65 years** who have completed the recommended vaccine series with both PCV13 (at any age) and PPSV23 (which was administered at age  $\geq 65$  years). Shared clinical decision-making recommendations are individually based and guided by a decision process between the health care provider and the patient.
- Adults aged **≥ 19-64 years with an immunocompromising condition**, a CSF leak, or a cochlear implant who have received both PCV13 and PPSV23 with incomplete vaccination status are recommended to complete their pneumococcal vaccine series by receiving either a single dose of PCV20 at an interval at least 5 years after the last pneumococcal vaccine dose or  $\geq 1$  dose of PPSV23.
- Adults aged **≥ 19-64 years who have received PCV13 only** are recommended to receive a single dose of PCV20 at an interval  $\geq 1$  year after receipt of the PCV13 dose or to receive  $\geq 1$  dose of PPSV23 to complete their pneumococcal vaccine series.
- Adults with **certain underlying medical conditions or risk factors** have increased risk for pneumococcal disease compared with adults without these conditions and thus have risk-based pneumococcal vaccine recommendations regardless of age.

## REFERENCES

1. Centers for Disease Control and Prevention. (2023). Pneumococcal Vaccination. Retrieved January 24, 2024, from <https://www.cdc.gov/vaccines/vpd/pneumo/index.html>.
2. Two new pneumococcal vaccines—Pevnar 20 and Vaxneuvance. (2021). *JAMA*, 326(24), 2521. <https://doi.org/10.1001/jama.2021.22119>.
3. Miwako, K., Pilishvili, T., Farrar, J., Leidner, A., Gierke, R., Prasad, N., Pedro, M., Campos-Outcalt, D., Morgan, R., Long, S., Poehling, K., Cohen, A. (2023). Pneumococcal vaccine for adults aged 19 years and older: recommendations of the advisory committee on immunization practices. *Recommendations and Reports of the Morbidity and Mortality Weekly Report*, 72(3), 1-39. <https://doi.org/10.15585/mmwr.rr7203a1>.
4. Centers for Disease Control and Prevention. (2023). Pneumococcal Vaccine Timing for Adults. Retrieved January 24, 2024, from <https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf>.